Azenta Q3 adjusted EPS beats estimates, revenue rises 12%
Azenta Q3 adjusted EPS beats estimates, revenue rises 12%
Overview
US life sciences solutions provider's fiscal Q3 revenue rose 12% yr/yr
Adjusted EPS for fiscal Q3 beat analyst expectations
Company repurchased $50 mln in shares under its buyback program
Outlook
Company expects FY26 reported revenue between $613 mln and $618 mln
Azenta expects FY26 adjusted EBITDA of $59 mln to $62 mln
Result Drivers
SEGMENT GROWTH - Higher revenue in Sample Management Solutions and Multiomics segments drove Q3 results
PRODUCT MIX - Sample Management Solutions growth was mainly driven by Sample Repository Solutions and Consumables and Instruments, partially offset by lower Automated Stores revenue
MARGIN PRESSURE - Gross margin declined due to unfavorable fixed-cost absorption from lower sales volumes and costs related to quality remediation and rework in Automated Stores
Company press release: ID:nPn7W22t1a
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Adjusted EPS | Beat | $0.16 | $0.11 (6 Analysts) |
Q3 Adjusted EBITDA |
| $18 mln |
|
Q3 Adjusted EBITDA Margin |
| 11.4% |
|
Q3 Operating Income |
| -$4.18 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Azenta, Inc is $29.00, about 2.9% below its August 3 closing price of $29.88
The stock recently traded at 52 times the next 12-month earnings vs. a P/E of 26 three months ago
Reuters Recommended Reads
Aug 4 - Revvity raises annual profit, revenue forecasts on strong diagnostics demand
Aug 4 - Waters lifts annual forecasts on strong lab-equipment and diagnostics demand
Aug 4 - Bio-Rad Q2 revenue beats analyst estimates on clinical diagnostics growth
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Azenta
See all newsUS RESEARCH ROUNDUP-Adobe, Domino's Pizza, Goldman Sachs
Brief: Azenta - Approves Restructuring Plan Within Multiomics Segment On October 5, 2026
Brooks Automation confidentially files for US IPO (updated)
U.S. STOCKS ON THE MOVE-Azenta, Qiagen NV, Capricor Therapeutics
Azenta names interim CEO after Marotta resigns; shares fall